In a new note to investors today, an analyst has provided a rating update for the Healthcare company, Aphria Inc (TSXV: APH). Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating, with a C$26.50 price target.

Bottomley wrote:

“We believe this deal provides Aphria with what could now be the largest international footprint in the industry, as well as increased technological proficiency in extraction, distillation and processing. Further, we believe Nuuvera has assets in place that could be meaningful contributors over the near to medium term. Since the end of January, industry valuations have experienced continued pressure and Aphria’s stock price has declined by >25%. We believe this may have been further magnified by media reports on Monday asserting that a number of Aphria’s executives and directors did not disclose personal holdings of Nuuvera during the acquisition process. We note that the quantum of NUU shares reported to have been held by APH insiders (less than one million) is immaterial to Nuuvera’s capital structure (<1%)."

According to TipRanks.com, Bottomley is ranked #365 out of 4768 analysts.

Aphria Inc has an analyst consensus of Moderate Buy, with a price target consensus of C$24.58.

Aphria Inc’s market cap is currently C$1.97B and has a P/E ratio of 76.2.

Aphria, Inc. engages in the production and supply of medical marijuana. Its products include alien dawg, champlian indica, grower’s blend, champlain-sativa and blueberry. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.

The company’s shares closed on Monday at C$12.95.